Trial Profile
An Open-Label Randomized Phase 3 Study of Capecitabine 6 months versus Capecitabine 12 months as Adjuvant Chemotherapy for Stage 3(Dukes'C) Colon Cancer Patients
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 22 Mar 2019
Price :
$35
*
At a glance
- Drugs Capecitabine (Primary)
- Indications Colon cancer; Colorectal cancer
- Focus Therapeutic Use
- 11 Oct 2016 Status changed from active, no longer recruiting to completed, according to to final results presented at the 41st European Society for Medical Oncology Congress.
- 11 Oct 2016 Primary endpoint (Disease-free survival) has not been met, according to final results presented at the 41st European Society for Medical Oncology Congress.
- 11 Oct 2016 Final results of this study, presented at the 41st European Society for Medical Oncology Congress.